Abstract
The migration of leukocytes from the blood stream to sites of infection is a key event in cellular immune response, mediated by multiple types of molecules including several adhesion receptors. The inhibition of adhesion receptors holds great promise for novel therapeutical strategies to treat chronic inflammatory disorders or autoimmune diseases. This review reports on recent advances in adhesion-based therapeutics and focuses on structural classification of selectin and integrin inhibitors.
Keywords: adhesion molecules, autoimmune disease, endothelium, inflammation, integrins, leukocytes, selectins
Mini-Reviews in Medicinal Chemistry
Title: Inhibitors of Membrane Receptors Involved with Leukocyte Extravasation
Volume: 5 Issue: 6
Author(s): Gerd Bendas
Affiliation:
Keywords: adhesion molecules, autoimmune disease, endothelium, inflammation, integrins, leukocytes, selectins
Abstract: The migration of leukocytes from the blood stream to sites of infection is a key event in cellular immune response, mediated by multiple types of molecules including several adhesion receptors. The inhibition of adhesion receptors holds great promise for novel therapeutical strategies to treat chronic inflammatory disorders or autoimmune diseases. This review reports on recent advances in adhesion-based therapeutics and focuses on structural classification of selectin and integrin inhibitors.
Export Options
About this article
Cite this article as:
Bendas Gerd, Inhibitors of Membrane Receptors Involved with Leukocyte Extravasation, Mini-Reviews in Medicinal Chemistry 2005; 5 (6) . https://dx.doi.org/10.2174/1389557054023279
DOI https://dx.doi.org/10.2174/1389557054023279 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials
Medicinal Chemistry Discovery of Potent Bruton’s Tyrosine Kinase Inhibitors Using Ligand Based Modeling
Anti-Cancer Agents in Medicinal Chemistry Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases
Current Medicinal Chemistry Transplantation of Genetically Modified Haematopoietic Stem Cells to Induce Antigen-Specific Tolerance as a Cure for Autoimmune Diseases
Current Stem Cell Research & Therapy Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews ImmunemiR - A Database of Prioritized Immune miRNA Disease Associations and its Interactome
MicroRNA Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders B-Cell Based Gene Therapy for Inducing Tolerance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry CCL17/Thymus and Activation-Related Chemokine: A biomarker for Churg-Strauss Syndrome?
Current Biomarkers (Discontinued) APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors
Current Drug Targets Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery